Who
Dennis Podlesak
Director
Company insider
Files Form 4 as: Director, Syndax Pharmaceuticals; Director, Alliqua BioMedical; Director, Tobira Therapeutics; Director, Avanir Pharmaceuticals; Director, Dov Pharmaceutical.
In numbers
- Trades disclosed
- 73
- Buys
- 2
- Sells
- 5
- Bought
- $207K
- Sold
- $2.8M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 13 Feb 2006
- Last trade
- 4 Feb 2026
- Last filed
- 6 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —48,000 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —48,000 at $0.00 | filing |
| 18 Aug 2025filed 18 Aug 2025 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,200 at $0.00 | filing |
| 18 Aug 2025filed 18 Aug 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $138K19,200 at $7.20 | filing |
| 18 Aug 2025filed 18 Aug 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $304K19,200 at $15.84 | filing |
| 15 Aug 2025filed 18 Aug 2025 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,400 at $0.00 | filing |
| 15 Aug 2025filed 18 Aug 2025 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,800 at $0.00 | filing |
| 15 Aug 2025filed 18 Aug 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $138K19,200 at $7.20 | filing |
| 15 Aug 2025filed 18 Aug 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $298K19,200 at $15.54 | filing |
| 14 Aug 2025filed 18 Aug 2025 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,200 at $0.00 | filing |
| 14 Aug 2025filed 18 Aug 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $138K19,200 at $7.20 | filing |
| 14 Aug 2025filed 18 Aug 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $272K19,200 at $14.19 | filing |
| 5 Feb 2025filed 7 Feb 2025 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Feb 2024filed 9 Feb 2024 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 2 Feb 2023filed 3 Feb 2023 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 16 Sep 2022filed 16 Sep 2022 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,556 at $0.00 | filing |
| 16 Sep 2022filed 16 Sep 2022 | SNDX Syndax Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,419 at $0.00 | filing |
| 16 Sep 2022filed 16 Sep 2022 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $34K5,419 at $6.32 | filing |
| 16 Sep 2022filed 16 Sep 2022 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $127K5,419 at $23.43 | filing |
| 16 Sep 2022filed 16 Sep 2022 | SNDX Syndax PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $42K6,556 at $6.35 | filing |
News
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down – Here's WhySNDX · tickerreport.com · 15 Oct 2026
0 headlines in the last 90 days name Dennis Podlesak; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.